Pharmaceutical

Theseus terminates its GI cancer drug development programme

Theseus Pharmaceuticals has terminated its pan-variant tyrosine kinase receptor (KIT) inhibitor (THE-630) drug development programme.

Jul 15, 2023 - 20:00
Theseus terminates its GI cancer drug development programme
Theseus Pharmaceuticals has terminated its pan-variant tyrosine kinase receptor (KIT) inhibitor (THE-630) drug development programme.
Read the original article

Tags:

Previous Article

CureVac turns up the heat in ongoing patent litigation with Pfizer

Next Article

Vistagen obtains Canadian Notice of Allowance for AV-101 patent

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Congress highlighted a chemo drug’s price to blast PBMs — but it’s not a PBM issue

STAT+: Congress highlighted a chemo drug’s price to bla...

May 23, 2023

Opinion: What STAT readers think about JPM’s locked lactation room, covering weight loss drugs, and more

Opinion: What STAT readers think about JPM’s locked lac...

Jan 14, 2024

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

May 15, 2024